Influenza Vaccine Market By Vaccine Type (Trivalent Flu Vaccines and Quadrivalent Flu Vaccines); By Influenza Type (Seasonal, Pandemic, and Others); By Type (Live Attenuated Influenza Vaccine (LAIV), Inactivated Influenza Vaccine (IIV), and Recombinant Influenza Vaccine (RIV)); By Manufacturing Technology (Egg Based and Cell Based); By Packaging (Prefilled Needleless Syringes and Single Dose and Multi-Dose Vial); By Dosage Form (Intramuscular Injection, Intradermal Shot, and Nasal Spray); By Age Group (6 months to 4 Years, 4 Years to 18 Years, 18 Years to 49 Years, 49 Years to 65 Years, and More than 65 Years); By Distribution Channel (Doctors’ Offices, Healthcare Clinics, Retail Pharmacies, Hospitals, and Others); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Influenza is defined as illness that occurs due to a viral infection which is generally respiratory in nature. Highly contagious, it mainly spreads through respiratory droplets. It also spreads due to contact with an infected person. Increasing number of influenza patients is escalating the demand for influenza vaccine, thereby fuelling the growth of global influenza vaccine market.
Many factors are driving the growth of global influenza vaccine market but the most important factor is the increasing awareness of the disease among people, increasing funding from government as well as from businesses in medical sector, and the fear of influenza pandemic. Other factors contributing to the growth of this market include upsurge in routine immunization programs in developed countries as well as developing countries, increasing awareness about influenza vaccines, increasing product launches and approvals, and the technological advancements. However, concerns pertaining to effectiveness of vaccines across different age groups owing to the difference in the immunity levels of children and adults, is impeding the growth of global influenza vaccine market.
The governments all over the world are taking initiatives to ensure the well-being of their citizens by minimizing the side effects of the influenza vaccines. The development of new vaccines as well as the improvement of the existing vaccines are contributing to the rise of the influenza vaccine market. Hence, investment and funding by different companies are anticipated to further proliferate the expansion of the global influenza vaccine market over the forecast period. The outbreak of the China-originated COVID-19 pandemic has affected many countries and the vaccine market got affected because demand is high and production is limited. In the University of Miami, a study found that flu vaccination offers some protection against severe coronavirus. Hence, boosting immunity and reducing the number of coronavirus patients showcases significant growth opportunity for the global influenza vaccine market over the future years.
The COVID-19 pandemic has led to a tremendous rise in concern about the health of children because little children have less immunity and coronavirus harms children as well as adults with low immunity maximum. As the influenza vaccine can save people from some symptoms of coronavirus, the increasing demand for influenza vaccines during the times of coronavirus pandemic has contributed to the growth of global influenza vaccine market. The flu jab can boost the innate immune system, providing protection against COVID-19 to a large extent.
Absolute Market Insights reports, the global influenza vaccine market is likely to grow at 6.6% CAGR during the 2021-2029 period, and reach a valuation of US$ 7824.08 Mn by 2029
Global Influenza Vaccine Market Revenue & Forecast, (US $ Million), 2021 – 2029
Vaccine Type Outlook:
On the basis of vaccine type, the global influenza vaccine market covers trivalent flu vaccines and quadrivalent flu vaccines. In 2020, the quadrivalent flu vaccines held the larger market share and during the forecast period, this category is expected to retain its position and become the fastest growing category in the market. Due to safety and immunogenicity, the demand for quadrivalent flu vaccines has increased. The standard-dose quadrivalent influenza shots are manufactured using virus grown in eggs. These vaccine include afluria quadrivalent, fluLaval quadrivalent, fluarix quadrivalent, and fluzone quadrivalent. As different influenza shots are licensed for different age groups, the four vaccines mentioned are approved for people 6 months of age and older.
Influenza Type Outlook:
The influenza type segment of global influenza vaccine market in this report has been broadly segmented into seasonal type, pandemic type, and others. The pandemic vaccine type is estimated to witness highest growth rate over the forecast period. Influenza pandemic is a global outbreak of a new influenza A virus. These viruses infect people easily and spread from person to person in an efficient and sustained way. For example, swine influenza (commonly known as swine flu), a respiratory disease of pigs caused by type A influenza viruses infected many humans few years ago.
Manufacturing Technology Outlook:
Based on manufacturing technology, the global influenza vaccine market is segmented into egg based technology and cell based technology. In 2020, egg based technology segment occupied larger market share.
During the forecast period, the cell based technology is anticipated to emerge as the fastest growing market. The cell culture-based segment is estimated to grow due to the rise in surgical procedures across the world which has become possible due to the availability of cell banking facilities. Cell-based technique makes the process of manufacturing influenza vaccines more flexible. Compared to traditional vaccines, it also offers enhanced protection. As the manufacturing is not dependent on egg supply, these vaccines have the potential to improve the effectiveness as they eliminate contamination that might occur in the egg during the manufacturing of vaccines.
Packaging Outlook:
Based on packaging, the global influenza vaccine market is bifurcated into prefilled needleless syringes and single dose & multi-dose vial. In 2020, single dose & multi-dose vial segment occupied larger market share.
The prefilled needleless syringes (PFSs) is expected to register highest growth rate over the period of next eight years. These syringes give advantages to providers who wish to not only improvise operational efficiency and minimize risk, but also improve patient safety in the clinical administration of vaccines. The growing recognition of the advantages of PFSs has made users prefer PFS over multidose vials (MDVs) for all types of vaccines, but most significantly, influenza vaccines. PFS reduces or eliminates vaccine waste. It increases administrative consistency by allowing consistency in vaccine administration across all locations and clinicians. It also improves efficiency as PFS can be prepared in short time. Compared to MDVs, PFS can save between 37 and 43 seconds per dose in preparation time. It also increases patients’ safety by reducing injection-related risks.
Dosage Form Outlook:
Based on dosage form, the global influenza vaccine market is classified into intramuscular injection, intradermal shot, and nasal spray. In 2020, intramuscular injection segment occupied larger market share. The nasal spray dosage form is witnessing traction in the global market due to growing awareness about new methods of dosages. The nasal spray flu vaccine can be given to people suffering from mild illnesses. This option is preferable for people who are not comfortable with needles. The nasal spray flu vaccine is approved for use in healthy non-pregnant individuals who are in the age-groups between 2 years old and 49 years old.
Age Group Outlook:
Based on age-group, the global influenza vaccine market is segmented into 6 months to 4 years, 4 years to 18 years, 18 years to 49 years, 49 years to 65 years, and more than 65 years. During the forecast period, 18 years to 49 years age-group segment is anticipated to witness highest growth rate. The recombinant quadrivalent influenza shot (Flublok Quadrivalent), an egg-free vaccine, has been approved for people aged 18 years and older. Many adults are allergic to all types of eggs. This vaccine can be suitable for them. A live attenuated influenza vaccine (FluMist Quadrivalent) has also been approved for people who have reached or crossed 49 years of age. This vaccine is administered intranasally. Hence, these two vaccines are contributing to the influenza vaccine market growth in this segment. However, live attenuated influenza vaccine is not supposed to be given to people who are pregnant, immunocompromised persons, and some other age-groups.
Region Outlook:
In 2020, North America held the largest share in the global influenza vaccine market. During the forecast period, Asia Pacific region is anticipated to witness highest growth rate due to rapid population growth along with active government support for healthcare research. These factors are contributing to the rise in demand for effective vaccines in this region. Increasing immunization rate and growing awareness regarding vaccination are the two factors contributing to the market growth.
Competitive Landscape Outlook:
The global influenza vaccine market landscape remains a highly innovative, competitive, and fragmented landscape. Despite major investments from many big players of medical sector enterprises, most companies do not have a sizable share of the market to influence pricing. Furthermore, the barriers to entry are financial in nature as the cost of production as well as storage can be high. Some key players in the global influenza vaccine market are Abbott, AstraZeneca, CSL Limited (Seqirus USA Inc.), Emergent BioSolutions Inc., F. Hoffmann-La Roche Ltd, GSK, Novavax Inc., SANOFI PASTEUR INC., Serum Institute of India Pvt. Ltd., and Sinovac Biotech Ltd.
Global Influenza Vaccine Market:
- By Vaccine Type
- Trivalent Flu Vaccines
- Quadrivalent Flu Vaccines
- By Influenza Type
- Seasonal
- Pandemic
- Others
- By Type
- Live Attenuated Influenza Vaccine (LAIV)
- Inactivated Influenza Vaccine (IIV)
- Recombinant Influenza Vaccine (RIV)
- By Manufacturing Technology
- Egg Based
- Cell Based
- By Packaging
- Prefilled Needleless Syringes
- Single Dose and Multi-Dose Vial
- By Dosage Form
- Intramuscular Injection
- Intradermal Shot
- Nasal Spray
- By Age Group
- 6 months to 4 Years
- 4 Years to 18 Years
- 18 Years to 49 Years
- 49 Years to 65 Years
- More than 65 Years
- By Distribution Channel
- Doctors’ Offices
- Healthcare Clinics
- Retail Pharmacies
- Hospitals
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2019
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Flu Vaccine [Influenza Vaccine] Market
6. Market
Synopsis: Flu Vaccine [Influenza
Vaccine] Market
7. Flu Vaccine
[Influenza Vaccine] Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Flu Vaccine [Influenza Vaccine] Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Flu Vaccine [Influenza Vaccine] Market
7.6. Porter’s Five Force Analysis
7.7. Impact of
Covid-19 on Flu Vaccine [Influenza Vaccine] Market
8. Global Flu
Vaccine [Influenza Vaccine] Market Analysis and Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn)
8.2. Global Flu
Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Vaccine
Type
8.2.1. Trivalent
Flu Vaccines
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2015 – 2020
8.2.1.3. Market
Forecast, 2021 – 2029
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 – 2020
8.2.1.5.1.2. Market
Forecast, 2021 – 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2020
8.2.1.5.2.2. Market
Forecast, 2021 – 2029
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2020
8.2.1.5.3.2. Market
Forecast, 2021 – 2029
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2020
8.2.1.5.4.2. Market
Forecast, 2021 – 2029
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 – 2020
8.2.1.5.5.2. Market
Forecast, 2021 – 2029
8.2.2. Quadrivalent
Flu Vaccines
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2015 – 2020
8.2.2.3. Market
Forecast, 2021 – 2029
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 – 2020
8.2.2.5.1.2. Market
Forecast, 2021 – 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2020
8.2.2.5.2.2. Market
Forecast, 2021 – 2029
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2020
8.2.2.5.3.2. Market
Forecast, 2021 – 2029
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2020
8.2.2.5.4.2. Market
Forecast, 2021 – 2029
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 – 2020
8.2.2.5.5.2. Market
Forecast, 2021 – 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By
Vaccine Type
9. Global Flu
Vaccine [Influenza Vaccine] Market Analysis and Forecasts, 2021 – 2029
9.1. Overview
9.2. Global Flu
Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Influenza
Type
9.2.1. Seasonal
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 – 2020
9.2.1.3. Market
Forecast, 2021 – 2029
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 – 2020
9.2.1.5.1.2. Market
Forecast, 2021 – 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2020
9.2.1.5.2.2. Market
Forecast, 2021 – 2029
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2020
9.2.1.5.3.2. Market
Forecast, 2021 – 2029
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2020
9.2.1.5.4.2. Market
Forecast, 2021 – 2029
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 – 2020
9.2.1.5.5.2. Market
Forecast, 2021 – 2029
9.2.2. Pandemic
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 – 2020
9.2.2.3. Market
Forecast, 2021 – 2029
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 – 2020
9.2.2.5.1.2. Market
Forecast, 2021 – 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2020
9.2.2.5.2.2. Market
Forecast, 2021 – 2029
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2020
9.2.2.5.3.2. Market
Forecast, 2021 – 2029
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2020
9.2.2.5.4.2. Market
Forecast, 2021 – 2029
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 – 2020
9.2.2.5.5.2. Market
Forecast, 2021 – 2029
9.2.3. Others
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2015 – 2020
9.2.3.3. Market
Forecast, 2021 – 2029
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2015 – 2020
9.2.3.5.1.2. Market
Forecast, 2021 – 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 – 2020
9.2.3.5.2.2. Market
Forecast, 2021 – 2029
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2015 – 2020
9.2.3.5.3.2. Market
Forecast, 2021 – 2029
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 – 2020
9.2.3.5.4.2. Market
Forecast, 2021 – 2029
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2015 – 2020
9.2.3.5.5.2. Market
Forecast, 2021 – 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Influenza Type
10. Global Flu
Vaccine [Influenza Vaccine] Market Analysis and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
10.2.1. Live
Attenuated Influenza Vaccine (LAIV)
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2015 – 2019
10.2.1.3. Market
Forecast, 2021 – 2029
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2015 – 2020
10.2.1.5.1.2. Market
Forecast, 2021 – 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 – 2020
10.2.1.5.2.2. Market
Forecast, 2021 – 2029
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2015 – 2020
10.2.1.5.3.2. Market
Forecast, 2021 – 2029
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 – 2020
10.2.1.5.4.2. Market
Forecast, 2021 – 2029
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2015 – 2020
10.2.1.5.5.2. Market
Forecast, 2021 – 2029
10.2.2. Inactivated
Influenza Vaccine (IIV)
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2015 – 2020
10.2.2.3. Market
Forecast, 2021 – 2029
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2015 – 2020
10.2.2.5.1.2. Market
Forecast, 2021 – 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2020
10.2.2.5.2.2. Market
Forecast, 2021 – 2029
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2020
10.2.2.5.3.2. Market
Forecast, 2021 – 2029
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2020
10.2.2.5.4.2. Market
Forecast, 2021 – 2029
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2015 – 2020
10.2.2.5.5.2. Market
Forecast, 2021 – 2029
10.2.3. Recombinant
Influenza Vaccine (RIV)
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2015 – 2020
10.2.3.3. Market
Forecast, 2021 – 2029
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2015 – 2020
10.2.3.5.1.2. Market
Forecast, 2021 – 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 – 2020
10.2.3.5.2.2. Market
Forecast, 2021 – 2029
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2015 – 2020
10.2.3.5.3.2. Market
Forecast, 2021 – 2029
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 – 2020
10.2.3.5.4.2. Market
Forecast, 2021 – 2029
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2015 – 2020
10.2.3.5.5.2. Market
Forecast, 2021 – 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By Type
11. Global Flu
Vaccine [Influenza Vaccine] Market Analysis and Forecasts, 2021 – 2029
11.1. Overview
11.2. Global
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
11.2.1. Egg
Based
11.2.1.1. Definition
11.2.1.2. Market
Estimation and Penetration, 2015 – 2019
11.2.1.3. Market
Forecast, 2021 – 2029
11.2.1.4. Compound
Annual Growth Rate (CAGR)
11.2.1.5. Regional
Bifurcation
11.2.1.5.1. North
America
11.2.1.5.1.1. Market
Estimation, 2015 – 2020
11.2.1.5.1.2. Market
Forecast, 2021 – 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 – 2020
11.2.1.5.2.2. Market
Forecast, 2021 – 2029
11.2.1.5.3. Asia
Pacific
11.2.1.5.3.1. Market
Estimation, 2015 – 2020
11.2.1.5.3.2. Market
Forecast, 2021 – 2029
11.2.1.5.4. Middle
East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 – 2020
11.2.1.5.4.2. Market
Forecast, 2021 – 2029
11.2.1.5.5. Latin
America
11.2.1.5.5.1. Market
Estimation, 2015 – 2020
11.2.1.5.5.2. Market
Forecast, 2021 – 2029
11.2.2. Cell
Based
11.2.2.1. Definition
11.2.2.2. Market
Estimation and Penetration, 2015 – 2019
11.2.2.3. Market
Forecast, 2021 – 2029
11.2.2.4. Compound
Annual Growth Rate (CAGR)
11.2.2.5. Regional
Bifurcation
11.2.2.5.1. North
America
11.2.2.5.1.1. Market
Estimation, 2015 – 2020
11.2.2.5.1.2. Market
Forecast, 2021 – 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 – 2020
11.2.2.5.2.2. Market
Forecast, 2021 – 2029
11.2.2.5.3. Asia
Pacific
11.2.2.5.3.1. Market
Estimation, 2015 – 2020
11.2.2.5.3.2. Market
Forecast, 2021 – 2029
11.2.2.5.4. Middle
East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 – 2020
11.2.2.5.4.2. Market
Forecast, 2021 – 2029
11.2.2.5.5. Latin
America
11.2.2.5.5.1. Market
Estimation, 2015 – 2020
11.2.2.5.5.2. Market
Forecast, 2021 – 2029
11.3. Key
Segment for Channeling Investments
11.3.1. By
Manufacturing Technology
12. Global Flu
Vaccine [Influenza Vaccine] Market Analysis and Forecasts, 2021 – 2029
12.1. Overview
12.2. Global
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
12.2.1. Prefilled
Needleless Syringes
12.2.1.1. Definition
12.2.1.2. Market
Estimation and Penetration, 2015 – 2020
12.2.1.3. Market
Forecast, 2021 – 2029
12.2.1.4. Compound
Annual Growth Rate (CAGR)
12.2.1.5. Regional
Bifurcation
12.2.1.5.1. North
America
12.2.1.5.1.1. Market
Estimation, 2015 – 2020
12.2.1.5.1.2. Market
Forecast, 2021 – 2029
12.2.1.5.2. Europe
12.2.1.5.2.1. Market
Estimation, 2015 – 2020
12.2.1.5.2.2. Market
Forecast, 2021 – 2029
12.2.1.5.3. Asia
Pacific
12.2.1.5.3.1. Market
Estimation, 2015 – 2020
12.2.1.5.3.2. Market
Forecast, 2021 – 2029
12.2.1.5.4. Middle
East and Africa
12.2.1.5.4.1. Market
Estimation, 2015 – 2020
12.2.1.5.4.2. Market
Forecast, 2021 – 2029
12.2.1.5.5. Latin
America
12.2.1.5.5.1. Market
Estimation, 2015 – 2020
12.2.1.5.5.2. Market
Forecast, 2021 – 2029
12.2.2. Single
Dose and Multi-Dose Vial
12.2.2.1. Definition
12.2.2.2. Market
Estimation and Penetration, 2015 – 2020
12.2.2.3. Market
Forecast, 2021 – 2029
12.2.2.4. Compound
Annual Growth Rate (CAGR)
12.2.2.5. Regional
Bifurcation
12.2.2.5.1. North
America
12.2.2.5.1.1. Market
Estimation, 2015 – 2020
12.2.2.5.1.2. Market
Forecast, 2021 – 2029
12.2.2.5.2. Europe
12.2.2.5.2.1. Market
Estimation, 2015 – 2020
12.2.2.5.2.2. Market
Forecast, 2021 – 2029
12.2.2.5.3. Asia
Pacific
12.2.2.5.3.1. Market
Estimation, 2015 – 2020
12.2.2.5.3.2. Market
Forecast, 2021 – 2029
12.2.2.5.4. Middle
East and Africa
12.2.2.5.4.1. Market
Estimation, 2015 – 2020
12.2.2.5.4.2. Market
Forecast, 2021 – 2029
12.2.2.5.5. Latin
America
12.2.2.5.5.1. Market
Estimation, 2015 – 2020
12.2.2.5.5.2. Market
Forecast, 2021 – 2029
12.3. Key
Segment for Channeling Investments
12.3.1. By
Packaging
13. Global Flu
Vaccine [Influenza Vaccine] Market Analysis and Forecasts, 2021 – 2029
13.1. Overview
13.2. Global Flu
Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Dosage
Form
13.2.1. Intramuscular
Injection
13.2.1.1. Definition
13.2.1.2. Market
Estimation and Penetration, 2015 – 2019
13.2.1.3. Market
Forecast, 2021 – 2029
13.2.1.4. Compound
Annual Growth Rate (CAGR)
13.2.1.5. Regional
Bifurcation
13.2.1.5.1. North
America
13.2.1.5.1.1. Market
Estimation, 2015 – 2020
13.2.1.5.1.2. Market
Forecast, 2021 – 2029
13.2.1.5.2. Europe
13.2.1.5.2.1. Market
Estimation, 2015 – 2020
13.2.1.5.2.2. Market
Forecast, 2021 – 2029
13.2.1.5.3. Asia
Pacific
13.2.1.5.3.1. Market
Estimation, 2015 – 2020
13.2.1.5.3.2. Market
Forecast, 2021 – 2029
13.2.1.5.4. Middle
East and Africa
13.2.1.5.4.1. Market
Estimation, 2015 – 2020
13.2.1.5.4.2. Market
Forecast, 2021 – 2029
13.2.1.5.5. Latin
America
13.2.1.5.5.1. Market
Estimation, 2015 – 2020
13.2.1.5.5.2. Market
Forecast, 2021 – 2029
13.2.2. Intradermal
Shot
13.2.2.1. Definition
13.2.2.2. Market
Estimation and Penetration, 2015 – 2020
13.2.2.3. Market
Forecast, 2021 – 2029
13.2.2.4. Compound
Annual Growth Rate (CAGR)
13.2.2.5. Regional
Bifurcation
13.2.2.5.1. North
America
13.2.2.5.1.1. Market
Estimation, 2015 – 2020
13.2.2.5.1.2. Market
Forecast, 2021 – 2029
13.2.2.5.2. Europe
13.2.2.5.2.1. Market
Estimation, 2015 – 2020
13.2.2.5.2.2. Market
Forecast, 2021 – 2029
13.2.2.5.3. Asia
Pacific
13.2.2.5.3.1. Market
Estimation, 2015 – 2020
13.2.2.5.3.2. Market
Forecast, 2021 – 2029
13.2.2.5.4. Middle
East and Africa
13.2.2.5.4.1. Market
Estimation, 2015 – 2020
13.2.2.5.4.2. Market
Forecast, 2021 – 2029
13.2.2.5.5. Latin
America
13.2.2.5.5.1. Market
Estimation, 2015 – 2020
13.2.2.5.5.2. Market
Forecast, 2021 – 2029
13.2.3. Nasal
Spray
13.2.3.1. Definition
13.2.3.2. Market
Estimation and Penetration, 2015 – 2020
13.2.3.3. Market
Forecast, 2021 – 2029
13.2.3.4. Compound
Annual Growth Rate (CAGR)
13.2.3.5. Regional
Bifurcation
13.2.3.5.1. North
America
13.2.3.5.1.1. Market
Estimation, 2015 – 2020
13.2.3.5.1.2. Market
Forecast, 2021 – 2029
13.2.3.5.2. Europe
13.2.3.5.2.1. Market
Estimation, 2015 – 2020
13.2.3.5.2.2. Market
Forecast, 2021 – 2029
13.2.3.5.3. Asia
Pacific
13.2.3.5.3.1. Market
Estimation, 2015 – 2020
13.2.3.5.3.2. Market
Forecast, 2021 – 2029
13.2.3.5.4. Middle
East and Africa
13.2.3.5.4.1. Market
Estimation, 2015 – 2020
13.2.3.5.4.2. Market
Forecast, 2021 – 2029
13.2.3.5.5. Latin
America
13.2.3.5.5.1. Market
Estimation, 2015 – 2020
13.2.3.5.5.2. Market
Forecast, 2021 – 2029
13.3. Key
Segment for Channeling Investments
13.3.1. By
Dosage Form
14. Global Flu
Vaccine [Influenza Vaccine] Market Analysis and Forecasts, 2021 – 2029
14.1. Overview
14.2. Global
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
14.2.1. 6
months to 4 Years
14.2.1.1. Definition
14.2.1.2. Market
Estimation and Penetration, 2015 – 2020
14.2.1.3. Market
Forecast, 2021 – 2029
14.2.1.4. Compound
Annual Growth Rate (CAGR)
14.2.1.5. Regional
Bifurcation
14.2.1.5.1. North
America
14.2.1.5.1.1. Market
Estimation, 2015 – 2020
14.2.1.5.1.2. Market
Forecast, 2021 – 2029
14.2.1.5.2. Europe
14.2.1.5.2.1. Market
Estimation, 2015 – 2020
14.2.1.5.2.2. Market
Forecast, 2021 – 2029
14.2.1.5.3. Asia
Pacific
14.2.1.5.3.1. Market
Estimation, 2015 – 2020
14.2.1.5.3.2. Market
Forecast, 2021 – 2029
14.2.1.5.4. Middle
East and Africa
14.2.1.5.4.1. Market
Estimation, 2015 – 2020
14.2.1.5.4.2. Market
Forecast, 2021 – 2029
14.2.1.5.5. Latin
America
14.2.1.5.5.1. Market
Estimation, 2015 – 2020
14.2.1.5.5.2. Market
Forecast, 2021 – 2029
14.2.2. 4 Years
to 18 Years
14.2.2.1. Definition
14.2.2.2. Market
Estimation and Penetration, 2015 – 2019
14.2.2.3. Market
Forecast, 2021 – 2029
14.2.2.4. Compound
Annual Growth Rate (CAGR)
14.2.2.5. Regional
Bifurcation
14.2.2.5.1. North
America
14.2.2.5.1.1. Market
Estimation, 2015 – 2020
14.2.2.5.1.2. Market
Forecast, 2021 – 2029
14.2.2.5.2. Europe
14.2.2.5.2.1. Market
Estimation, 2015 – 2020
14.2.2.5.2.2. Market
Forecast, 2021 – 2029
14.2.2.5.3. Asia
Pacific
14.2.2.5.3.1. Market
Estimation, 2015 – 2020
14.2.2.5.3.2. Market
Forecast, 2021 – 2029
14.2.2.5.4. Middle
East and Africa
14.2.2.5.4.1. Market
Estimation, 2015 – 2020
14.2.2.5.4.2. Market
Forecast, 2021 – 2029
14.2.2.5.5. Latin
America
14.2.2.5.5.1. Market
Estimation, 2015 – 2020
14.2.2.5.5.2. Market
Forecast, 2021 – 2029
14.2.3. 18
Years to 49 Years
14.2.3.1. Definition
14.2.3.2. Market
Estimation and Penetration, 2015 – 2019
14.2.3.3. Market
Forecast, 2021 – 2029
14.2.3.4. Compound
Annual Growth Rate (CAGR)
14.2.3.5. Regional
Bifurcation
14.2.3.5.1. North
America
14.2.3.5.1.1. Market
Estimation, 2015 – 2020
14.2.3.5.1.2. Market
Forecast, 2021 – 2029
14.2.3.5.2. Europe
14.2.3.5.2.1. Market
Estimation, 2015 – 2020
14.2.3.5.2.2. Market
Forecast, 2021 – 2029
14.2.3.5.3. Asia
Pacific
14.2.3.5.3.1. Market
Estimation, 2015 – 2020
14.2.3.5.3.2. Market
Forecast, 2021 – 2029
14.2.3.5.4. Middle
East and Africa
14.2.3.5.4.1. Market
Estimation, 2015 – 2020
14.2.3.5.4.2. Market
Forecast, 2021 – 2029
14.2.3.5.5. Latin
America
14.2.3.5.5.1. Market
Estimation, 2015 – 2020
14.2.3.5.5.2. Market
Forecast, 2021 – 2029
14.2.4. 49
Years to 65 Years
14.2.4.1. Definition
14.2.4.2. Market
Estimation and Penetration, 2015 – 2020
14.2.4.3. Market
Forecast, 2021 – 2029
14.2.4.4. Compound
Annual Growth Rate (CAGR)
14.2.4.5. Regional
Bifurcation
14.2.4.5.1. North
America
14.2.4.5.1.1. Market
Estimation, 2015 – 2019
14.2.4.5.1.2. Market
Forecast, 2021 – 2029
14.2.4.5.2. Europe
14.2.4.5.2.1. Market
Estimation, 2015 – 2020
14.2.4.5.2.2. Market
Forecast, 2021 – 2029
14.2.4.5.3. Asia
Pacific
14.2.4.5.3.1. Market
Estimation, 2015 – 2020
14.2.4.5.3.2. Market
Forecast, 2021 – 2029
14.2.4.5.4. Middle
East and Africa
14.2.4.5.4.1. Market
Estimation, 2015 – 2020
14.2.4.5.4.2. Market
Forecast, 2021 – 2029
14.2.4.5.5. Latin
America
14.2.4.5.5.1. Market
Estimation, 2015 – 2020
14.2.4.5.5.2. Market
Forecast, 2021 – 2029
14.2.5. More
than 65 Years
14.2.5.1. Definition
14.2.5.2. Market
Estimation and Penetration, 2015 – 2020
14.2.5.3. Market
Forecast, 2021 – 2029
14.2.5.4. Compound
Annual Growth Rate (CAGR)
14.2.5.5. Regional
Bifurcation
14.2.5.5.1. North
America
14.2.5.5.1.1. Market
Estimation, 2015 – 2020
14.2.5.5.1.2. Market
Forecast, 2021 – 2029
14.2.5.5.2. Europe
14.2.5.5.2.1. Market
Estimation, 2015 – 2020
14.2.5.5.2.2. Market
Forecast, 2021 – 2029
14.2.5.5.3. Asia
Pacific
14.2.5.5.3.1. Market
Estimation, 2015 – 2020
14.2.5.5.3.2. Market
Forecast, 2021 – 2029
14.2.5.5.4. Middle
East and Africa
14.2.5.5.4.1. Market
Estimation, 2015 – 2020
14.2.5.5.4.2. Market
Forecast, 2021 – 2029
14.2.5.5.5. Latin
America
14.2.5.5.5.1. Market
Estimation, 2015 – 2020
14.2.5.5.5.2. Market
Forecast, 2021 – 2029
14.3. Key
Segment for Channeling Investments
14.3.1. By Age
Group
15. Global Flu
Vaccine [Influenza Vaccine] Market Analysis and Forecasts, 2021 – 2029
15.1. Overview
15.2. Global
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.2.1. Doctors’
Offices
15.2.1.1. Definition
15.2.1.2. Market
Estimation and Penetration, 2015 – 2020
15.2.1.3. Market
Forecast, 2021 – 2029
15.2.1.4. Compound
Annual Growth Rate (CAGR)
15.2.1.5. Regional
Bifurcation
15.2.1.5.1. North
America
15.2.1.5.1.1. Market
Estimation, 2015 – 2020
15.2.1.5.1.2. Market
Forecast, 2021 – 2029
15.2.1.5.2. Europe
15.2.1.5.2.1. Market
Estimation, 2015 – 2020
15.2.1.5.2.2. Market
Forecast, 2021 – 2029
15.2.1.5.3. Asia
Pacific
15.2.1.5.3.1. Market
Estimation, 2015 – 2020
15.2.1.5.3.2. Market
Forecast, 2021 – 2029
15.2.1.5.4. Middle
East and Africa
15.2.1.5.4.1. Market
Estimation, 2015 – 2020
15.2.1.5.4.2. Market
Forecast, 2021 – 2029
15.2.1.5.5. Latin
America
15.2.1.5.5.1. Market
Estimation, 2015 – 2020
15.2.1.5.5.2. Market
Forecast, 2021 – 2029
15.2.2. Healthcare
Clinics
15.2.2.1. Definition
15.2.2.2. Market
Estimation and Penetration, 2015 – 2020
15.2.2.3. Market
Forecast, 2021 – 2029
15.2.2.4. Compound
Annual Growth Rate (CAGR)
15.2.2.5. Regional
Bifurcation
15.2.2.5.1. North
America
15.2.2.5.1.1. Market
Estimation, 2015 – 2020
15.2.2.5.1.2. Market
Forecast, 2021 – 2029
15.2.2.5.2. Europe
15.2.2.5.2.1. Market
Estimation, 2015 – 2020
15.2.2.5.2.2. Market
Forecast, 2021 – 2029
15.2.2.5.3. Asia
Pacific
15.2.2.5.3.1. Market
Estimation, 2015 – 2020
15.2.2.5.3.2. Market
Forecast, 2021 – 2029
15.2.2.5.4. Middle
East and Africa
15.2.2.5.4.1. Market
Estimation, 2015 – 2020
15.2.2.5.4.2. Market
Forecast, 2021 – 2029
15.2.2.5.5. Latin
America
15.2.2.5.5.1. Market
Estimation, 2015 – 2020
15.2.2.5.5.2. Market
Forecast, 2021 – 2029
15.2.3. Retail
Pharmacies
15.2.3.1. Definition
15.2.3.2. Market
Estimation and Penetration, 2015 – 2020
15.2.3.3. Market
Forecast, 2021 – 2029
15.2.3.4. Compound
Annual Growth Rate (CAGR)
15.2.3.5. Regional
Bifurcation
15.2.3.5.1. North
America
15.2.3.5.1.1. Market
Estimation, 2015 – 2020
15.2.3.5.1.2. Market
Forecast, 2021 – 2029
15.2.3.5.2. Europe
15.2.3.5.2.1. Market
Estimation, 2015 – 2020
15.2.3.5.2.2. Market
Forecast, 2021 – 2029
15.2.3.5.3. Asia
Pacific
15.2.3.5.3.1. Market
Estimation, 2015 – 2020
15.2.3.5.3.2. Market
Forecast, 2021 – 2029
15.2.3.5.4. Middle
East and Africa
15.2.3.5.4.1. Market
Estimation, 2015 – 2020
15.2.3.5.4.2. Market
Forecast, 2021 – 2029
15.2.3.5.5. Latin
America
15.2.3.5.5.1. Market
Estimation, 2015 – 2020
15.2.3.5.5.2. Market
Forecast, 2021 – 2029
15.2.4. Hospitals
15.2.4.1. Definition
15.2.4.2. Market
Estimation and Penetration, 2015 – 2020
15.2.4.3. Market
Forecast, 2021 – 2029
15.2.4.4. Compound
Annual Growth Rate (CAGR)
15.2.4.5. Regional
Bifurcation
15.2.4.5.1. North
America
15.2.4.5.1.1. Market
Estimation, 2015 – 2020
15.2.4.5.1.2. Market
Forecast, 2021 – 2029
15.2.4.5.2. Europe
15.2.4.5.2.1. Market
Estimation, 2015 – 2020
15.2.4.5.2.2. Market
Forecast, 2021 – 2029
15.2.4.5.3. Asia
Pacific
15.2.4.5.3.1. Market
Estimation, 2015 – 2020
15.2.4.5.3.2. Market
Forecast, 2021 – 2029
15.2.4.5.4. Middle
East and Africa
15.2.4.5.4.1. Market
Estimation, 2015 – 2020
15.2.4.5.4.2. Market
Forecast, 2021 – 2029
15.2.4.5.5. Latin
America
15.2.4.5.5.1. Market
Estimation, 2015 – 2020
15.2.4.5.5.2. Market
Forecast, 2021 – 2029
15.2.5. Others
15.2.5.1. Definition
15.2.5.2. Market
Estimation and Penetration, 2015 – 2020
15.2.5.3. Market
Forecast, 2021 – 2029
15.2.5.4. Compound
Annual Growth Rate (CAGR)
15.2.5.5. Regional
Bifurcation
15.2.5.5.1. North
America
15.2.5.5.1.1. Market
Estimation, 2015 – 2020
15.2.5.5.1.2. Market
Forecast, 2021 – 2029
15.2.5.5.2. Europe
15.2.5.5.2.1. Market
Estimation, 2015 – 2020
15.2.5.5.2.2. Market
Forecast, 2021 – 2029
15.2.5.5.3. Asia
Pacific
15.2.5.5.3.1. Market
Estimation, 2015 – 2020
15.2.5.5.3.2. Market
Forecast, 2021 – 2029
15.2.5.5.4. Middle
East and Africa
15.2.5.5.4.1. Market
Estimation, 2015 – 2020
15.2.5.5.4.2. Market
Forecast, 2021 – 2029
15.2.5.5.5. Latin
America
15.2.5.5.5.1. Market
Estimation, 2015 – 2020
15.2.5.5.5.2. Market
Forecast, 2021 – 2029
15.3. Key
Segment for Channeling Investments
15.3.1. By
Distribution Channel
16. North
America Flu Vaccine [Influenza Vaccine] Market Analysis and Forecasts, 2021 -
2029
16.1. Overview
16.1.1. North
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn)
16.2. North
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Vaccine Type
16.2.1. Trivalent
Flu Vaccines
16.2.2. Quadrivalent
Flu Vaccines
16.3. North
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Influenza Type
16.3.1. Seasonal
16.3.2. Pandemic
16.3.3. Others
16.4. North
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Type
16.4.1. Live
Attenuated Influenza Vaccine (LAIV)
16.4.2. Inactivated
Influenza Vaccine (IIV)
16.4.3. Recombinant
Influenza Vaccine (RIV)
16.5. North
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Manufacturing Technology
16.5.1. Egg
Based
16.5.2. Cell
Based
16.6. North
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Packaging
16.6.1. Prefilled
Needleless Syringes
16.6.2. Single
Dose and Multi-Dose Vial
16.7. North
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Dosage Form
16.7.1. Intramuscular
Injection
16.7.2. Intradermal
Shot
16.7.3. Nasal
Spray
16.8. North
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Age Group
16.8.1. 6
months to 4 Years
16.8.2. 4 Years
to 18 Years
16.8.3. 18
Years to 49 Years
16.8.4. 49
Years to 65 Years
16.8.5. More
than 65 Years
16.9. North
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
16.9.1. Doctors’
Offices
16.9.2. Healthcare
Clinics
16.9.3. Retail
Pharmacies
16.9.4. Hospitals
16.9.5. Others
16.10. North
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Country
16.10.1. U.S
16.10.1.1. U.S
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
16.10.1.1.1. Trivalent
Flu Vaccines
16.10.1.1.2. Quadrivalent
Flu Vaccines
16.10.1.2. U.S
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
16.10.1.2.1. Seasonal
16.10.1.2.2. Pandemic
16.10.1.2.3. Others
16.10.1.3. U.S
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
16.10.1.3.1. Live
Attenuated Influenza Vaccine (LAIV)
16.10.1.3.2. Inactivated
Influenza Vaccine (IIV)
16.10.1.3.3. Recombinant
Influenza Vaccine (RIV)
16.10.1.4. U.S
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
16.10.1.4.1. Egg
Based
16.10.1.4.2. Cell
Based
16.10.1.5. U.S
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
16.10.1.5.1. Prefilled
Needleless Syringes
16.10.1.5.2. Single
Dose and Multi-Dose Vial
16.10.1.6. U.S
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
16.10.1.6.1. Intramuscular
Injection
16.10.1.6.2. Intradermal
Shot
16.10.1.6.3. Nasal
Spray
16.10.1.7. U.S
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
16.10.1.7.1. 6
months to 4 Years
16.10.1.7.2. 4 Years
to 18 Years
16.10.1.7.3. 18
Years to 49 Years
16.10.1.7.4. 49
Years to 65 Years
16.10.1.7.5. More
than 65 Years
16.10.1.8. U.S
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
16.10.1.8.1. Doctors’
Offices
16.10.1.8.2. Healthcare
Clinics
16.10.1.8.3. Retail
Pharmacies
16.10.1.8.4. Hospitals
16.10.1.8.5. Others
16.10.2. Canada
16.10.2.1. Canada
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
16.10.2.1.1. Trivalent
Flu Vaccines
16.10.2.1.2. Quadrivalent
Flu Vaccines
16.10.2.2. Canada
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
16.10.2.2.1. Seasonal
16.10.2.2.2. Pandemic
16.10.2.2.3. Others
16.10.2.3. Canada
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
16.10.2.3.1. Live
Attenuated Influenza Vaccine (LAIV)
16.10.2.3.2. Inactivated
Influenza Vaccine (IIV)
16.10.2.3.3. Recombinant
Influenza Vaccine (RIV)
16.10.2.4. Canada
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
16.10.2.4.1. Egg
Based
16.10.2.4.2. Cell
Based
16.10.2.5. Canada
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
16.10.2.5.1. Prefilled
Needleless Syringes
16.10.2.5.2. Single
Dose and Multi-Dose Vial
16.10.2.6. Canada
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
16.10.2.6.1. Intramuscular
Injection
16.10.2.6.2. Intradermal
Shot
16.10.2.6.3. Nasal
Spray
16.10.2.7. Canada
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age Group
16.10.2.7.1. 6
months to 4 Years
16.10.2.7.2. 4
Years to 18 Years
16.10.2.7.3. 18
Years to 49 Years
16.10.2.7.4. 49
Years to 65 Years
16.10.2.7.5. More
than 65 Years
16.10.2.8. Canada
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
16.10.2.8.1. Doctors’
Offices
16.10.2.8.2. Healthcare
Clinics
16.10.2.8.3. Retail
Pharmacies
16.10.2.8.4. Hospitals
16.10.2.8.5. Others
16.10.3. Mexico
16.10.3.1. Mexico
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
16.10.3.1.1. Trivalent
Flu Vaccines
16.10.3.1.2. Quadrivalent
Flu Vaccines
16.10.3.2. Mexico
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
16.10.3.2.1. Seasonal
16.10.3.2.2. Pandemic
16.10.3.2.3. Others
16.10.3.3. Mexico
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
16.10.3.3.1. Live
Attenuated Influenza Vaccine (LAIV)
16.10.3.3.2. Inactivated
Influenza Vaccine (IIV)
16.10.3.3.3. Recombinant
Influenza Vaccine (RIV)
16.10.3.4. Mexico
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
16.10.3.4.1. Egg
Based
16.10.3.4.2. Cell
Based
16.10.3.5. Mexico
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
16.10.3.5.1. Prefilled
Needleless Syringes
16.10.3.5.2. Single
Dose and Multi-Dose Vial
16.10.3.6. Mexico
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
16.10.3.6.1. Intramuscular
Injection
16.10.3.6.2. Intradermal
Shot
16.10.3.6.3. Nasal
Spray
16.10.3.7. Mexico
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
16.10.3.7.1. 6
months to 4 Years
16.10.3.7.2. 4
Years to 18 Years
16.10.3.7.3. 18
Years to 49 Years
16.10.3.7.4. 49
Years to 65 Years
16.10.3.7.5. More
than 65 Years
16.10.3.8. Mexico
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
16.10.3.8.1. Doctors’
Offices
16.10.3.8.2. Healthcare
Clinics
16.10.3.8.3. Retail
Pharmacies
16.10.3.8.4. Hospitals
16.10.3.8.5. Others
16.10.4. Rest
of North America
16.10.4.1. Rest
of North America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Vaccine Type
16.10.4.1.1. Trivalent
Flu Vaccines
16.10.4.1.2. Quadrivalent
Flu Vaccines
16.10.4.2. Rest
of North America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Influenza Type
16.10.4.2.1. Seasonal
16.10.4.2.2. Pandemic
16.10.4.2.3. Others
16.10.4.3. Rest
of North America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Type
16.10.4.3.1. Live
Attenuated Influenza Vaccine (LAIV)
16.10.4.3.2. Inactivated
Influenza Vaccine (IIV)
16.10.4.3.3. Recombinant
Influenza Vaccine (RIV)
16.10.4.4. Rest
of North America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Manufacturing Technology
16.10.4.4.1. Egg
Based
16.10.4.4.2. Cell
Based
16.10.4.5. Rest
of North America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Packaging
16.10.4.5.1. Prefilled
Needleless Syringes
16.10.4.5.2. Single
Dose and Multi-Dose Vial
16.10.4.6. Rest
of North America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
16.10.4.6.1. Intramuscular
Injection
16.10.4.6.2. Intradermal
Shot
16.10.4.6.3. Nasal
Spray
16.10.4.7. Rest
of North America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Age Group
16.10.4.7.1. 6
months to 4 Years
16.10.4.7.2. 4
Years to 18 Years
16.10.4.7.3. 18
Years to 49 Years
16.10.4.7.4. 49
Years to 65 Years
16.10.4.7.5. More
than 65 Years
16.10.4.8. Rest
of North America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
16.10.4.8.1. Doctors’
Offices
16.10.4.8.2. Healthcare
Clinics
16.10.4.8.3. Retail
Pharmacies
16.10.4.8.4. Hospitals
16.10.4.8.5. Others
16.11. Key
Segment for Channeling Investments
16.11.1. By
Country
16.11.2. By
Vaccine Type
16.11.3. By
Influenza Type
16.11.4. By
Type
16.11.5. By
Manufacturing Technology
16.11.6. By
Packaging
16.11.7. By
Dosage Form
16.11.8. By Age
Group
16.11.9. By
Distribution Channel
17. Europe Flu
Vaccine [Influenza Vaccine] Market Analysis and Forecasts, 2021 - 2029
17.1. Overview
17.1.1. Europe
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn)
17.2. Europe
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
17.2.1. Trivalent
Flu Vaccines
17.2.2. Quadrivalent
Flu Vaccines
17.3. Europe
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
17.3.1. Seasonal
17.3.2. Pandemic
17.3.3. Others
17.4. Europe
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
17.4.1. Live
Attenuated Influenza Vaccine (LAIV)
17.4.2. Inactivated
Influenza Vaccine (IIV)
17.4.3. Recombinant
Influenza Vaccine (RIV)
17.5. Europe
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
17.5.1. Egg
Based
17.5.2. Cell
Based
17.6. Europe
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
17.6.1. Prefilled
Needleless Syringes
17.6.2. Single
Dose and Multi-Dose Vial
17.7. Europe
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
17.7.1. Intramuscular
Injection
17.7.2. Intradermal
Shot
17.7.3. Nasal
Spray
17.8. Europe
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
17.8.1. 6
months to 4 Years
17.8.2. 4 Years
to 18 Years
17.8.3. 18
Years to 49 Years
17.8.4. 49
Years to 65 Years
17.8.5. More
than 65 Years
17.9. Europe
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
17.9.1. Doctors’
Offices
17.9.2. Healthcare
Clinics
17.9.3. Retail
Pharmacies
17.9.4. Hospitals
17.9.5. Others
17.10. Europe
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Country
17.10.1. France
17.10.1.1. France
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
17.10.1.1.1. Trivalent
Flu Vaccines
17.10.1.1.2. Quadrivalent
Flu Vaccines
17.10.1.2. France
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
17.10.1.2.1. Seasonal
17.10.1.2.2. Pandemic
17.10.1.2.3. Others
17.10.1.3. France
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
17.10.1.3.1. Live
Attenuated Influenza Vaccine (LAIV)
17.10.1.3.2. Inactivated
Influenza Vaccine (IIV)
17.10.1.3.3. Recombinant
Influenza Vaccine (RIV)
17.10.1.4. France
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
17.10.1.4.1. Egg
Based
17.10.1.4.2. Cell
Based
17.10.1.5. France
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
17.10.1.5.1. Prefilled
Needleless Syringes
17.10.1.5.2. Single
Dose and Multi-Dose Vial
17.10.1.6. France
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
17.10.1.6.1. Intramuscular
Injection
17.10.1.6.2. Intradermal
Shot
17.10.1.6.3. Nasal
Spray
17.10.1.7. France
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
17.10.1.7.1. 6
months to 4 Years
17.10.1.7.2. 4
Years to 18 Years
17.10.1.7.3. 18
Years to 49 Years
17.10.1.7.4. 49
Years to 65 Years
17.10.1.7.5. More
than 65 Years
17.10.1.8. France
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
17.10.1.8.1. Doctors’
Offices
17.10.1.8.2. Healthcare
Clinics
17.10.1.8.3. Retail
Pharmacies
17.10.1.8.4. Hospitals
17.10.1.8.5. Others
17.10.2. The UK
17.10.2.1. The
UK Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
17.10.2.1.1. Trivalent
Flu Vaccines
17.10.2.1.2. Quadrivalent
Flu Vaccines
17.10.2.2. The
UK Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
17.10.2.2.1. Seasonal
17.10.2.2.2. Pandemic
17.10.2.2.3. Others
17.10.2.3. The
UK Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Type
17.10.2.3.1. Live
Attenuated Influenza Vaccine (LAIV)
17.10.2.3.2. Inactivated
Influenza Vaccine (IIV)
17.10.2.3.3. Recombinant
Influenza Vaccine (RIV)
17.10.2.4. The
UK Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
17.10.2.4.1. Egg
Based
17.10.2.4.2. Cell
Based
17.10.2.5. The
UK Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
17.10.2.5.1. Prefilled
Needleless Syringes
17.10.2.5.2. Single
Dose and Multi-Dose Vial
17.10.2.6. The
UK Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
17.10.2.6.1. Intramuscular
Injection
17.10.2.6.2. Intradermal
Shot
17.10.2.6.3. Nasal
Spray
17.10.2.7. The
UK Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Age Group
17.10.2.7.1. 6
months to 4 Years
17.10.2.7.2. 4
Years to 18 Years
17.10.2.7.3. 18
Years to 49 Years
17.10.2.7.4. 49
Years to 65 Years
17.10.2.7.5. More
than 65 Years
17.10.2.8. The
UK Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
17.10.2.8.1. Doctors’
Offices
17.10.2.8.2. Healthcare
Clinics
17.10.2.8.3. Retail
Pharmacies
17.10.2.8.4. Hospitals
17.10.2.8.5. Others
17.10.3. Spain
17.10.3.1. Spain
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
17.10.3.1.1. Trivalent
Flu Vaccines
17.10.3.1.2. Quadrivalent
Flu Vaccines
17.10.3.2. Spain
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
17.10.3.2.1. Seasonal
17.10.3.2.2. Pandemic
17.10.3.2.3. Others
17.10.3.3. Spain
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
17.10.3.3.1. Live
Attenuated Influenza Vaccine (LAIV)
17.10.3.3.2. Inactivated
Influenza Vaccine (IIV)
17.10.3.3.3. Recombinant
Influenza Vaccine (RIV)
17.10.3.4. Spain
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
17.10.3.4.1. Egg
Based
17.10.3.4.2. Cell
Based
17.10.3.5. Spain
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
17.10.3.5.1. Prefilled
Needleless Syringes
17.10.3.5.2. Single
Dose and Multi-Dose Vial
17.10.3.6. Spain
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
17.10.3.6.1. Intramuscular
Injection
17.10.3.6.2. Intradermal
Shot
17.10.3.6.3. Nasal
Spray
17.10.3.7. Spain
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
17.10.3.7.1. 6
months to 4 Years
17.10.3.7.2. 4
Years to 18 Years
17.10.3.7.3. 18
Years to 49 Years
17.10.3.7.4. 49
Years to 65 Years
17.10.3.7.5. More
than 65 Years
17.10.3.8. Spain
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
17.10.3.8.1. Doctors’
Offices
17.10.3.8.2. Healthcare
Clinics
17.10.3.8.3. Retail
Pharmacies
17.10.3.8.4. Hospitals
17.10.3.8.5. Others
17.10.4. Germany
17.10.4.1. Germany
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
17.10.4.1.1. Trivalent
Flu Vaccines
17.10.4.1.2. Quadrivalent
Flu Vaccines
17.10.4.2. Germany
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
17.10.4.2.1. Seasonal
17.10.4.2.2. Pandemic
17.10.4.2.3. Others
17.10.4.3. Germany
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
17.10.4.3.1. Live
Attenuated Influenza Vaccine (LAIV)
17.10.4.3.2. Inactivated
Influenza Vaccine (IIV)
17.10.4.3.3. Recombinant
Influenza Vaccine (RIV)
17.10.4.4. Germany
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
17.10.4.4.1. Egg
Based
17.10.4.4.2. Cell
Based
17.10.4.5. Germany
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
17.10.4.5.1. Prefilled
Needleless Syringes
17.10.4.5.2. Single
Dose and Multi-Dose Vial
17.10.4.6. Germany
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
17.10.4.6.1. Intramuscular
Injection
17.10.4.6.2. Intradermal
Shot
17.10.4.6.3. Nasal
Spray
17.10.4.7. Germany
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
17.10.4.7.1. 6
months to 4 Years
17.10.4.7.2. 4
Years to 18 Years
17.10.4.7.3. 18
Years to 49 Years
17.10.4.7.4. 49
Years to 65 Years
17.10.4.7.5. More
than 65 Years
17.10.4.8. Germany
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
17.10.4.8.1. Doctors’
Offices
17.10.4.8.2. Healthcare
Clinics
17.10.4.8.3. Retail
Pharmacies
17.10.4.8.4. Hospitals
17.10.4.8.5. Others
17.10.5. Italy
17.10.5.1. Italy
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
17.10.5.1.1. Trivalent
Flu Vaccines
17.10.5.1.2. Quadrivalent
Flu Vaccines
17.10.5.2. Italy
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
17.10.5.2.1. Seasonal
17.10.5.2.2. Pandemic
17.10.5.2.3. Others
17.10.5.3. Italy
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
17.10.5.3.1. Live
Attenuated Influenza Vaccine (LAIV)
17.10.5.3.2. Inactivated
Influenza Vaccine (IIV)
17.10.5.3.3. Recombinant
Influenza Vaccine (RIV)
17.10.5.4. Italy
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
17.10.5.4.1. Egg
Based
17.10.5.4.2. Cell
Based
17.10.5.5. Italy
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
17.10.5.5.1. Prefilled
Needleless Syringes
17.10.5.5.2. Single
Dose and Multi-Dose Vial
17.10.5.6. Italy
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
17.10.5.6.1. Intramuscular
Injection
17.10.5.6.2. Intradermal
Shot
17.10.5.6.3. Nasal
Spray
17.10.5.7. Italy
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
17.10.5.7.1. 6
months to 4 Years
17.10.5.7.2. 4
Years to 18 Years
17.10.5.7.3. 18
Years to 49 Years
17.10.5.7.4. 49
Years to 65 Years
17.10.5.7.5. More
than 65 Years
17.10.5.8. Italy
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
17.10.5.8.1. Doctors’
Offices
17.10.5.8.2. Healthcare
Clinics
17.10.5.8.3. Retail
Pharmacies
17.10.5.8.4. Hospitals
17.10.5.8.5. Others
17.10.6. Nordic
Countries
17.10.6.1. Nordic
Countries Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Vaccine Type
17.10.6.1.1. Trivalent
Flu Vaccines
17.10.6.1.2. Quadrivalent
Flu Vaccines
17.10.6.2. Nordic
Countries Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Influenza Type
17.10.6.2.1. Seasonal
17.10.6.2.2. Pandemic
17.10.6.2.3. Others
17.10.6.3. Nordic
Countries Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Type
17.10.6.3.1. Live
Attenuated Influenza Vaccine (LAIV)
17.10.6.3.2. Inactivated
Influenza Vaccine (IIV)
17.10.6.3.3. Recombinant
Influenza Vaccine (RIV)
17.10.6.4. Nordic
Countries Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Manufacturing Technology
17.10.6.4.1. Egg
Based
17.10.6.4.2. Cell
Based
17.10.6.5. Nordic
Countries Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Packaging
17.10.6.5.1. Prefilled
Needleless Syringes
17.10.6.5.2. Single
Dose and Multi-Dose Vial
17.10.6.6. Nordic
Countries Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
17.10.6.6.1. Intramuscular
Injection
17.10.6.6.2. Intradermal
Shot
17.10.6.6.3. Nasal
Spray
17.10.6.7. Nordic
Countries Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Age Group
17.10.6.7.1. 6
months to 4 Years
17.10.6.7.2. 4
Years to 18 Years
17.10.6.7.3. 18
Years to 49 Years
17.10.6.7.4. 49
Years to 65 Years
17.10.6.7.5. More
than 65 Years
17.10.6.8. Nordic
Countries Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
17.10.6.8.1. Doctors’
Offices
17.10.6.8.2. Healthcare
Clinics
17.10.6.8.3. Retail
Pharmacies
17.10.6.8.4. Hospitals
17.10.6.8.5. Others
17.10.6.9. Nordic
Countries Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Country
17.10.6.9.1. Denmark
17.10.6.9.2. Finland
17.10.6.9.3. Iceland
17.10.6.9.4. Sweden
17.10.6.9.5. Norway
17.10.7. Benelux
Union
17.10.7.1. Benelux
Union Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
17.10.7.1.1. Trivalent
Flu Vaccines
17.10.7.1.2. Quadrivalent
Flu Vaccines
17.10.7.2. Benelux
Union Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
17.10.7.2.1. Seasonal
17.10.7.2.2. Pandemic
17.10.7.2.3. Others
17.10.7.3. Benelux
Union Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Type
17.10.7.3.1. Live
Attenuated Influenza Vaccine (LAIV)
17.10.7.3.2. Inactivated
Influenza Vaccine (IIV)
17.10.7.3.3. Recombinant
Influenza Vaccine (RIV)
17.10.7.4. Benelux
Union Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
17.10.7.4.1. Egg
Based
17.10.7.4.2. Cell
Based
17.10.7.5. Benelux
Union Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
17.10.7.5.1. Prefilled
Needleless Syringes
17.10.7.5.2. Single
Dose and Multi-Dose Vial
17.10.7.6. Benelux
Union Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
17.10.7.6.1. Intramuscular
Injection
17.10.7.6.2. Intradermal
Shot
17.10.7.6.3. Nasal
Spray
17.10.7.7. Benelux
Union Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Age Group
17.10.7.7.1. 6
months to 4 Years
17.10.7.7.2. 4
Years to 18 Years
17.10.7.7.3. 18
Years to 49 Years
17.10.7.7.4. 49
Years to 65 Years
17.10.7.7.5. More
than 65 Years
17.10.7.8. Benelux
Union Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
17.10.7.8.1. Doctors’
Offices
17.10.7.8.2. Healthcare
Clinics
17.10.7.8.3. Retail
Pharmacies
17.10.7.8.4. Hospitals
17.10.7.8.5. Others
17.10.7.9. Benelux
Union Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Country
17.10.7.9.1. Belgium
17.10.7.9.2. The
Netherlands
17.10.7.9.3. Luxembourg
17.10.8. Rest
of Europe
17.10.8.1. Rest
of Europe Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Vaccine Type
17.10.8.1.1. Trivalent
Flu Vaccines
17.10.8.1.2. Quadrivalent
Flu Vaccines
17.10.8.2. Rest
of Europe Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Influenza Type
17.10.8.2.1. Seasonal
17.10.8.2.2. Pandemic
17.10.8.2.3. Others
17.10.8.3. Rest
of Europe Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Type
17.10.8.3.1. Live
Attenuated Influenza Vaccine (LAIV)
17.10.8.3.2. Inactivated
Influenza Vaccine (IIV)
17.10.8.3.3. Recombinant
Influenza Vaccine (RIV)
17.10.8.4. Rest
of Europe Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Manufacturing Technology
17.10.8.4.1. Egg
Based
17.10.8.4.2. Cell
Based
17.10.8.5. Rest
of Europe Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Packaging
17.10.8.5.1. Prefilled
Needleless Syringes
17.10.8.5.2. Single
Dose and Multi-Dose Vial
17.10.8.6. Rest
of Europe Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
17.10.8.6.1. Intramuscular
Injection
17.10.8.6.2. Intradermal
Shot
17.10.8.6.3. Nasal
Spray
17.10.8.7. Rest
of Europe Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Age Group
17.10.8.7.1. 6
months to 4 Years
17.10.8.7.2. 4
Years to 18 Years
17.10.8.7.3. 18
Years to 49 Years
17.10.8.7.4. 49
Years to 65 Years
17.10.8.7.5. More
than 65 Years
17.10.8.8. Rest
of Europe Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
17.10.8.8.1. Doctors’
Offices
17.10.8.8.2. Healthcare
Clinics
17.10.8.8.3. Retail
Pharmacies
17.10.8.8.4. Hospitals
17.10.8.8.5. Others
17.11. Key
Segment for Channeling Investments
17.11.1. By
Country
17.11.2. By
Vaccine Type
17.11.3. By Influenza
Type
17.11.4. By
Type
17.11.5. By
Manufacturing Technology
17.11.6. By
Packaging
17.11.7. By
Dosage Form
17.11.8. By Age
Group
17.11.9. By
Distribution Channel
18. Asia
Pacific Flu Vaccine [Influenza Vaccine] Market Analysis and Forecasts, 2021 -
2029
18.1. Overview
18.1.1. Asia
Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn)
18.2. Asia
Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Vaccine Type
18.2.1. Trivalent
Flu Vaccines
18.2.2. Quadrivalent
Flu Vaccines
18.3. Asia
Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Influenza Type
18.3.1. Seasonal
18.3.2. Pandemic
18.3.3. Others
18.4. Asia
Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Type
18.4.1. Live
Attenuated Influenza Vaccine (LAIV)
18.4.2. Inactivated
Influenza Vaccine (IIV)
18.4.3. Recombinant
Influenza Vaccine (RIV)
18.5. Asia Pacific
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
18.5.1. Egg
Based
18.5.2. Cell
Based
18.6. Asia
Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Packaging
18.6.1. Prefilled
Needleless Syringes
18.6.2. Single
Dose and Multi-Dose Vial
18.7. Asia
Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Dosage Form
18.7.1. Intramuscular
Injection
18.7.2. Intradermal
Shot
18.7.3. Nasal
Spray
18.8. Asia
Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Age Group
18.8.1. 6
months to 4 Years
18.8.2. 4 Years
to 18 Years
18.8.3. 18
Years to 49 Years
18.8.4. 49
Years to 65 Years
18.8.5. More
than 65 Years
18.9. Asia
Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
18.9.1. Doctors’
Offices
18.9.2. Healthcare
Clinics
18.9.3. Retail
Pharmacies
18.9.4. Hospitals
18.9.5. Others
18.10. Asia
Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Country
18.10.1. China
18.10.1.1. China
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
18.10.1.1.1. Trivalent
Flu Vaccines
18.10.1.1.2. Quadrivalent
Flu Vaccines
18.10.1.2. China
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
18.10.1.2.1. Seasonal
18.10.1.2.2. Pandemic
18.10.1.2.3. Others
18.10.1.3. China
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
18.10.1.3.1. Live
Attenuated Influenza Vaccine (LAIV)
18.10.1.3.2. Inactivated
Influenza Vaccine (IIV)
18.10.1.3.3. Recombinant
Influenza Vaccine (RIV)
18.10.1.4. China
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
18.10.1.4.1. Egg
Based
18.10.1.4.2. Cell
Based
18.10.1.5. China
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
18.10.1.5.1. Prefilled
Needleless Syringes
18.10.1.5.2. Single
Dose and Multi-Dose Vial
18.10.1.6. China
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
18.10.1.6.1. Intramuscular
Injection
18.10.1.6.2. Intradermal
Shot
18.10.1.6.3. Nasal
Spray
18.10.1.7. China
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
18.10.1.7.1. 6
months to 4 Years
18.10.1.7.2. 4
Years to 18 Years
18.10.1.7.3. 18
Years to 49 Years
18.10.1.7.4. 49
Years to 65 Years
18.10.1.7.5. More
than 65 Years
18.10.1.8. China
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
18.10.1.8.1. Doctors’
Offices
18.10.1.8.2. Healthcare
Clinics
18.10.1.8.3. Retail
Pharmacies
18.10.1.8.4. Hospitals
18.10.1.8.5. Others
18.10.2. Japan
18.10.2.1. Japan
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
18.10.2.1.1. Trivalent
Flu Vaccines
18.10.2.1.2. Quadrivalent
Flu Vaccines
18.10.2.2. Japan
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
18.10.2.2.1. Seasonal
18.10.2.2.2. Pandemic
18.10.2.2.3. Others
18.10.2.3. Japan
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
18.10.2.3.1. Live
Attenuated Influenza Vaccine (LAIV)
18.10.2.3.2. Inactivated
Influenza Vaccine (IIV)
18.10.2.3.3. Recombinant
Influenza Vaccine (RIV)
18.10.2.4. Japan
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
18.10.2.4.1. Egg
Based
18.10.2.4.2. Cell
Based
18.10.2.5. Japan
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
18.10.2.5.1. Prefilled
Needleless Syringes
18.10.2.5.2. Single
Dose and Multi-Dose Vial
18.10.2.6. Japan
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
18.10.2.6.1. Intramuscular
Injection
18.10.2.6.2. Intradermal
Shot
18.10.2.6.3. Nasal
Spray
18.10.2.7. Japan
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
18.10.2.7.1. 6
months to 4 Years
18.10.2.7.2. 4
Years to 18 Years
18.10.2.7.3. 18
Years to 49 Years
18.10.2.7.4. 49
Years to 65 Years
18.10.2.7.5. More
than 65 Years
18.10.2.8. Japan
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
18.10.2.8.1. Doctors’
Offices
18.10.2.8.2. Healthcare
Clinics
18.10.2.8.3. Retail
Pharmacies
18.10.2.8.4. Hospitals
18.10.2.8.5. Others
18.10.3. India
18.10.3.1. India
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
18.10.3.1.1. Trivalent
Flu Vaccines
18.10.3.1.2. Quadrivalent
Flu Vaccines
18.10.3.2. India
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
18.10.3.2.1. Seasonal
18.10.3.2.2. Pandemic
18.10.3.2.3. Others
18.10.3.3. India
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
18.10.3.3.1. Live
Attenuated Influenza Vaccine (LAIV)
18.10.3.3.2. Inactivated
Influenza Vaccine (IIV)
18.10.3.3.3. Recombinant
Influenza Vaccine (RIV)
18.10.3.4. India
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
18.10.3.4.1. Egg
Based
18.10.3.4.2. Cell
Based
18.10.3.5. India
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
18.10.3.5.1. Prefilled
Needleless Syringes
18.10.3.5.2. Single
Dose and Multi-Dose Vial
18.10.3.6. India
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
18.10.3.6.1. Intramuscular
Injection
18.10.3.6.2. Intradermal
Shot
18.10.3.6.3. Nasal
Spray
18.10.3.7. India
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
18.10.3.7.1. 6
months to 4 Years
18.10.3.7.2. 4
Years to 18 Years
18.10.3.7.3. 18
Years to 49 Years
18.10.3.7.4. 49
Years to 65 Years
18.10.3.7.5. More
than 65 Years
18.10.3.8. India
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
18.10.3.8.1. Doctors’
Offices
18.10.3.8.2. Healthcare
Clinics
18.10.3.8.3. Retail
Pharmacies
18.10.3.8.4. Hospitals
18.10.3.8.5. Others
18.10.4. New
Zealand
18.10.4.1. New
Zealand Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Vaccine Type
18.10.4.1.1. Trivalent
Flu Vaccines
18.10.4.1.2. Quadrivalent
Flu Vaccines
18.10.4.2. New
Zealand Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Influenza Type
18.10.4.2.1. Seasonal
18.10.4.2.2. Pandemic
18.10.4.2.3. Others
18.10.4.3. New
Zealand Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Type
18.10.4.3.1. Live
Attenuated Influenza Vaccine (LAIV)
18.10.4.3.2. Inactivated
Influenza Vaccine (IIV)
18.10.4.3.3. Recombinant
Influenza Vaccine (RIV)
18.10.4.4. New
Zealand Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Manufacturing Technology
18.10.4.4.1. Egg
Based
18.10.4.4.2. Cell
Based
18.10.4.5. New
Zealand Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Packaging
18.10.4.5.1. Prefilled
Needleless Syringes
18.10.4.5.2. Single
Dose and Multi-Dose Vial
18.10.4.6. New
Zealand Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Dosage Form
18.10.4.6.1. Intramuscular
Injection
18.10.4.6.2. Intradermal
Shot
18.10.4.6.3. Nasal
Spray
18.10.4.7. New
Zealand Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Age Group
18.10.4.7.1. 6
months to 4 Years
18.10.4.7.2. 4
Years to 18 Years
18.10.4.7.3. 18
Years to 49 Years
18.10.4.7.4. 49
Years to 65 Years
18.10.4.7.5. More
than 65 Years
18.10.4.8. New
Zealand Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
18.10.4.8.1. Doctors’
Offices
18.10.4.8.2. Healthcare
Clinics
18.10.4.8.3. Retail
Pharmacies
18.10.4.8.4. Hospitals
18.10.4.8.5. Others
18.10.5. Australia
18.10.5.1. Australia
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
18.10.5.1.1. Trivalent
Flu Vaccines
18.10.5.1.2. Quadrivalent
Flu Vaccines
18.10.5.2. Australia
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
18.10.5.2.1. Seasonal
18.10.5.2.2. Pandemic
18.10.5.2.3. Others
18.10.5.3. Australia
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
18.10.5.3.1. Live
Attenuated Influenza Vaccine (LAIV)
18.10.5.3.2. Inactivated
Influenza Vaccine (IIV)
18.10.5.3.3. Recombinant
Influenza Vaccine (RIV)
18.10.5.4. Australia
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
18.10.5.4.1. Egg
Based
18.10.5.4.2. Cell
Based
18.10.5.5. Australia
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
18.10.5.5.1. Prefilled
Needleless Syringes
18.10.5.5.2. Single
Dose and Multi-Dose Vial
18.10.5.6. Australia
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
18.10.5.6.1. Intramuscular
Injection
18.10.5.6.2. Intradermal
Shot
18.10.5.6.3. Nasal
Spray
18.10.5.7. Australia
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
18.10.5.7.1. 6
months to 4 Years
18.10.5.7.2. 4
Years to 18 Years
18.10.5.7.3. 18
Years to 49 Years
18.10.5.7.4. 49
Years to 65 Years
18.10.5.7.5. More
than 65 Years
18.10.5.8. Australia
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
18.10.5.8.1. Doctors’
Offices
18.10.5.8.2. Healthcare
Clinics
18.10.5.8.3. Retail
Pharmacies
18.10.5.8.4. Hospitals
18.10.5.8.5. Others
18.10.6. South
Korea
18.10.6.1. South
Korea Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
18.10.6.1.1. Trivalent
Flu Vaccines
18.10.6.1.2. Quadrivalent
Flu Vaccines
18.10.6.2. South
Korea Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
18.10.6.2.1. Seasonal
18.10.6.2.2. Pandemic
18.10.6.2.3. Others
18.10.6.3. South
Korea Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Type
18.10.6.3.1. Live
Attenuated Influenza Vaccine (LAIV)
18.10.6.3.2. Inactivated
Influenza Vaccine (IIV)
18.10.6.3.3. Recombinant
Influenza Vaccine (RIV)
18.10.6.4. South
Korea Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
18.10.6.4.1. Egg
Based
18.10.6.4.2. Cell
Based
18.10.6.5. South
Korea Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
18.10.6.5.1. Prefilled
Needleless Syringes
18.10.6.5.2. Single
Dose and Multi-Dose Vial
18.10.6.6. South
Korea Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
18.10.6.6.1. Intramuscular
Injection
18.10.6.6.2. Intradermal
Shot
18.10.6.6.3. Nasal
Spray
18.10.6.7. South
Korea Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Age Group
18.10.6.7.1. 6
months to 4 Years
18.10.6.7.2. 4
Years to 18 Years
18.10.6.7.3. 18
Years to 49 Years
18.10.6.7.4. 49
Years to 65 Years
18.10.6.7.5. More
than 65 Years
18.10.6.8. South
Korea Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
18.10.6.8.1. Doctors’
Offices
18.10.6.8.2. Healthcare
Clinics
18.10.6.8.3. Retail
Pharmacies
18.10.6.8.4. Hospitals
18.10.6.8.5. Others
18.10.7. Southeast
Asia
18.10.7.1. Southeast
Asia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
18.10.7.1.1. Trivalent
Flu Vaccines
18.10.7.1.2. Quadrivalent
Flu Vaccines
18.10.7.2. Southeast
Asia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
18.10.7.2.1. Seasonal
18.10.7.2.2. Pandemic
18.10.7.2.3. Others
18.10.7.3. Southeast
Asia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Type
18.10.7.3.1. Live
Attenuated Influenza Vaccine (LAIV)
18.10.7.3.2. Inactivated
Influenza Vaccine (IIV)
18.10.7.3.3. Recombinant
Influenza Vaccine (RIV)
18.10.7.4. Southeast
Asia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
18.10.7.4.1. Egg
Based
18.10.7.4.2. Cell
Based
18.10.7.5. Southeast
Asia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
18.10.7.5.1. Prefilled
Needleless Syringes
18.10.7.5.2. Single
Dose and Multi-Dose Vial
18.10.7.6. Southeast
Asia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
18.10.7.6.1. Intramuscular
Injection
18.10.7.6.2. Intradermal
Shot
18.10.7.6.3. Nasal
Spray
18.10.7.7. Southeast
Asia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Age Group
18.10.7.7.1. 6
months to 4 Years
18.10.7.7.2. 4
Years to 18 Years
18.10.7.7.3. 18
Years to 49 Years
18.10.7.7.4. 49
Years to 65 Years
18.10.7.7.5. More
than 65 Years
18.10.7.8. Southeast
Asia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
18.10.7.8.1. Doctors’
Offices
18.10.7.8.2. Healthcare
Clinics
18.10.7.8.3. Retail
Pharmacies
18.10.7.8.4. Hospitals
18.10.7.8.5. Others
18.10.7.9. Southeast
Asia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Country
18.10.7.9.1. Indonesia
18.10.7.9.2. Thailand
18.10.7.9.3. Malaysia
18.10.7.9.4. Singapore
18.10.7.9.5. Rest
of Southeast Asia
18.10.8. Rest
of Asia Pacific
18.10.8.1. Rest
of Asia Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Vaccine Type
18.10.8.1.1. Trivalent
Flu Vaccines
18.10.8.1.2. Quadrivalent
Flu Vaccines
18.10.8.2. Rest
of Asia Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Influenza Type
18.10.8.2.1. Seasonal
18.10.8.2.2. Pandemic
18.10.8.2.3. Others
18.10.8.3. Rest
of Asia Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Type
18.10.8.3.1. Live
Attenuated Influenza Vaccine (LAIV)
18.10.8.3.2. Inactivated
Influenza Vaccine (IIV)
18.10.8.3.3. Recombinant
Influenza Vaccine (RIV)
18.10.8.4. Rest
of Asia Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Manufacturing Technology
18.10.8.4.1. Egg
Based
18.10.8.4.2. Cell
Based
18.10.8.5. Rest
of Asia Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Packaging
18.10.8.5.1. Prefilled
Needleless Syringes
18.10.8.5.2. Single
Dose and Multi-Dose Vial
18.10.8.6. Rest
of Asia Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
18.10.8.6.1. Intramuscular
Injection
18.10.8.6.2. Intradermal
Shot
18.10.8.6.3. Nasal
Spray
18.10.8.7. Rest
of Asia Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Age Group
18.10.8.7.1. 6
months to 4 Years
18.10.8.7.2. 4
Years to 18 Years
18.10.8.7.3. 18
Years to 49 Years
18.10.8.7.4. 49
Years to 65 Years
18.10.8.7.5. More
than 65 Years
18.10.8.8. Rest
of Asia Pacific Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
18.10.8.8.1. Doctors’
Offices
18.10.8.8.2. Healthcare
Clinics
18.10.8.8.3. Retail
Pharmacies
18.10.8.8.4. Hospitals
18.10.8.8.5. Others
18.11. Key
Segment for Channeling Investments
18.11.1. By
Country
18.11.2. By
Vaccine Type
18.11.3. By Influenza
Type
18.11.4. By
Type
18.11.5. By
Manufacturing Technology
18.11.6. By
Packaging
18.11.7. By
Dosage Form
18.11.8. By Age
Group
18.11.9. By
Distribution Channel
19. Middle
East and Africa Flu Vaccine [Influenza Vaccine] Market Analysis and Forecasts, 2021
- 2029
19.1. Overview
19.1.1. Middle
East and Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn)
19.2. Middle
East and Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Vaccine Type
19.2.1. Trivalent
Flu Vaccines
19.2.2. Quadrivalent
Flu Vaccines
19.3. Middle
East and Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Influenza Type
19.3.1. Seasonal
19.3.2. Pandemic
19.3.3. Others
19.4. Middle
East and Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Type
19.4.1. Live
Attenuated Influenza Vaccine (LAIV)
19.4.2. Inactivated
Influenza Vaccine (IIV)
19.4.3. Recombinant
Influenza Vaccine (RIV)
19.5. Middle
East and Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Manufacturing Technology
19.5.1. Egg
Based
19.5.2. Cell
Based
19.6. Middle
East and Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Packaging
19.6.1. Prefilled
Needleless Syringes
19.6.2. Single
Dose and Multi-Dose Vial
19.7. Middle
East and Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
19.7.1. Intramuscular
Injection
19.7.2. Intradermal
Shot
19.7.3. Nasal
Spray
19.8. Middle
East and Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Age Group
19.8.1. 6
months to 4 Years
19.8.2. 4 Years
to 18 Years
19.8.3. 18
Years to 49 Years
19.8.4. 49
Years to 65 Years
19.8.5. More
than 65 Years
19.9. Middle
East and Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
19.9.1. Doctors’
Offices
19.9.2. Healthcare
Clinics
19.9.3. Retail
Pharmacies
19.9.4. Hospitals
19.9.5. Others
19.10. Middle
East and Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Country
19.10.1. Saudi
Arabia
19.10.1.1. Saudi
Arabia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Vaccine Type
19.10.1.1.1. Trivalent
Flu Vaccines
19.10.1.1.2. Quadrivalent
Flu Vaccines
19.10.1.2. Saudi
Arabia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Influenza Type
19.10.1.2.1. Seasonal
19.10.1.2.2. Pandemic
19.10.1.2.3. Others
19.10.1.3. Saudi
Arabia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Type
19.10.1.3.1. Live
Attenuated Influenza Vaccine (LAIV)
19.10.1.3.2. Inactivated
Influenza Vaccine (IIV)
19.10.1.3.3. Recombinant
Influenza Vaccine (RIV)
19.10.1.4. Saudi
Arabia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Manufacturing Technology
19.10.1.4.1. Egg
Based
19.10.1.4.2. Cell
Based
19.10.1.5. Saudi
Arabia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Packaging
19.10.1.5.1. Prefilled
Needleless Syringes
19.10.1.5.2. Single
Dose and Multi-Dose Vial
19.10.1.6. Saudi
Arabia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Dosage Form
19.10.1.6.1. Intramuscular
Injection
19.10.1.6.2. Intradermal
Shot
19.10.1.6.3. Nasal
Spray
19.10.1.7. Saudi
Arabia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Age Group
19.10.1.7.1. 6
months to 4 Years
19.10.1.7.2. 4
Years to 18 Years
19.10.1.7.3. 18
Years to 49 Years
19.10.1.7.4. 49
Years to 65 Years
19.10.1.7.5. More
than 65 Years
19.10.1.8. Saudi
Arabia Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
19.10.1.8.1. Doctors’
Offices
19.10.1.8.2. Healthcare
Clinics
19.10.1.8.3. Retail
Pharmacies
19.10.1.8.4. Hospitals
19.10.1.8.5. Others
19.10.2. UAE
19.10.2.1. UAE
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
19.10.2.1.1. Trivalent
Flu Vaccines
19.10.2.1.2. Quadrivalent
Flu Vaccines
19.10.2.2. UAE
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
19.10.2.2.1. Seasonal
19.10.2.2.2. Pandemic
19.10.2.2.3. Others
19.10.2.3. UAE
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
19.10.2.3.1. Live
Attenuated Influenza Vaccine (LAIV)
19.10.2.3.2. Inactivated
Influenza Vaccine (IIV)
19.10.2.3.3. Recombinant
Influenza Vaccine (RIV)
19.10.2.4. UAE
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
19.10.2.4.1. Egg
Based
19.10.2.4.2. Cell
Based
19.10.2.5. UAE
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
19.10.2.5.1. Prefilled
Needleless Syringes
19.10.2.5.2. Single
Dose and Multi-Dose Vial
19.10.2.6. UAE
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
19.10.2.6.1. Intramuscular
Injection
19.10.2.6.2. Intradermal
Shot
19.10.2.6.3. Nasal
Spray
19.10.2.7. UAE
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
19.10.2.7.1. 6
months to 4 Years
19.10.2.7.2. 4
Years to 18 Years
19.10.2.7.3. 18
Years to 49 Years
19.10.2.7.4. 49
Years to 65 Years
19.10.2.7.5. More
than 65 Years
19.10.2.8. UAE
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
19.10.2.8.1. Doctors’
Offices
19.10.2.8.2. Healthcare
Clinics
19.10.2.8.3. Retail
Pharmacies
19.10.2.8.4. Hospitals
19.10.2.8.5. Others
19.10.3. Egypt
19.10.3.1. Egypt
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
19.10.3.1.1. Trivalent
Flu Vaccines
19.10.3.1.2. Quadrivalent
Flu Vaccines
19.10.3.2. Egypt
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
19.10.3.2.1. Seasonal
19.10.3.2.2. Pandemic
19.10.3.2.3. Others
19.10.3.3. Egypt
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
19.10.3.3.1. Live
Attenuated Influenza Vaccine (LAIV)
19.10.3.3.2. Inactivated
Influenza Vaccine (IIV)
19.10.3.3.3. Recombinant
Influenza Vaccine (RIV)
19.10.3.4. Egypt
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
19.10.3.4.1. Egg
Based
19.10.3.4.2. Cell
Based
19.10.3.5. Egypt
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
19.10.3.5.1. Prefilled
Needleless Syringes
19.10.3.5.2. Single
Dose and Multi-Dose Vial
19.10.3.6. Egypt
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
19.10.3.6.1. Intramuscular
Injection
19.10.3.6.2. Intradermal
Shot
19.10.3.6.3. Nasal
Spray
19.10.3.7. Egypt
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
19.10.3.7.1. 6
months to 4 Years
19.10.3.7.2. 4
Years to 18 Years
19.10.3.7.3. 18
Years to 49 Years
19.10.3.7.4. 49
Years to 65 Years
19.10.3.7.5. More
than 65 Years
19.10.3.8. Egypt
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
19.10.3.8.1. Doctors’
Offices
19.10.3.8.2. Healthcare
Clinics
19.10.3.8.3. Retail
Pharmacies
19.10.3.8.4. Hospitals
19.10.3.8.5. Others
19.10.4. Kuwait
19.10.4.1. Kuwait
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
19.10.4.1.1. Trivalent
Flu Vaccines
19.10.4.1.2. Quadrivalent
Flu Vaccines
19.10.4.2. Kuwait
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
19.10.4.2.1. Seasonal
19.10.4.2.2. Pandemic
19.10.4.2.3. Others
19.10.4.3. Kuwait
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
19.10.4.3.1. Live
Attenuated Influenza Vaccine (LAIV)
19.10.4.3.2. Inactivated
Influenza Vaccine (IIV)
19.10.4.3.3. Recombinant
Influenza Vaccine (RIV)
19.10.4.4. Kuwait
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
19.10.4.4.1. Egg
Based
19.10.4.4.2. Cell
Based
19.10.4.5. Kuwait
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
19.10.4.5.1. Prefilled
Needleless Syringes
19.10.4.5.2. Single
Dose and Multi-Dose Vial
19.10.4.6. Kuwait
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
19.10.4.6.1. Intramuscular
Injection
19.10.4.6.2. Intradermal
Shot
19.10.4.6.3. Nasal
Spray
19.10.4.7. Kuwait
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
19.10.4.7.1. 6
months to 4 Years
19.10.4.7.2. 4
Years to 18 Years
19.10.4.7.3. 18
Years to 49 Years
19.10.4.7.4. 49
Years to 65 Years
19.10.4.7.5. More
than 65 Years
19.10.4.8. Kuwait
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
19.10.4.8.1. Doctors’
Offices
19.10.4.8.2. Healthcare
Clinics
19.10.4.8.3. Retail
Pharmacies
19.10.4.8.4. Hospitals
19.10.4.8.5. Others
19.10.5. South
Africa
19.10.5.1. South
Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Vaccine Type
19.10.5.1.1. Trivalent
Flu Vaccines
19.10.5.1.2. Quadrivalent
Flu Vaccines
19.10.5.2. South
Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Influenza Type
19.10.5.2.1. Seasonal
19.10.5.2.2. Pandemic
19.10.5.2.3. Others
19.10.5.3. South
Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Type
19.10.5.3.1. Live
Attenuated Influenza Vaccine (LAIV)
19.10.5.3.2. Inactivated
Influenza Vaccine (IIV)
19.10.5.3.3. Recombinant
Influenza Vaccine (RIV)
19.10.5.4. South
Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Manufacturing Technology
19.10.5.4.1. Egg
Based
19.10.5.4.2. Cell
Based
19.10.5.5. South
Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Packaging
19.10.5.5.1. Prefilled
Needleless Syringes
19.10.5.5.2. Single
Dose and Multi-Dose Vial
19.10.5.6. South
Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Dosage Form
19.10.5.6.1. Intramuscular
Injection
19.10.5.6.2. Intradermal
Shot
19.10.5.6.3. Nasal
Spray
19.10.5.7. South
Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Age Group
19.10.5.7.1. 6
months to 4 Years
19.10.5.7.2. 4
Years to 18 Years
19.10.5.7.3. 18
Years to 49 Years
19.10.5.7.4. 49
Years to 65 Years
19.10.5.7.5. More
than 65 Years
19.10.5.8. South
Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
19.10.5.8.1. Doctors’
Offices
19.10.5.8.2. Healthcare
Clinics
19.10.5.8.3. Retail
Pharmacies
19.10.5.8.4. Hospitals
19.10.5.8.5. Others
19.10.6. Rest
of Middle East & Africa
19.10.6.1. Rest
of Middle East & Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$
Mn) and Forecasts, By Vaccine Type
19.10.6.1.1. Trivalent
Flu Vaccines
19.10.6.1.2. Quadrivalent
Flu Vaccines
19.10.6.2. Rest
of Middle East & Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$
Mn) and Forecasts, By Influenza Type
19.10.6.2.1. Seasonal
19.10.6.2.2. Pandemic
19.10.6.2.3. Others
19.10.6.3. Rest
of Middle East & Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$
Mn) and Forecasts, By Type
19.10.6.3.1. Live
Attenuated Influenza Vaccine (LAIV)
19.10.6.3.2. Inactivated
Influenza Vaccine (IIV)
19.10.6.3.3. Recombinant
Influenza Vaccine (RIV)
19.10.6.4. Rest
of Middle East & Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$
Mn) and Forecasts, By Manufacturing Technology
19.10.6.4.1. Egg
Based
19.10.6.4.2. Cell
Based
19.10.6.5. Rest
of Middle East & Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$
Mn) and Forecasts, By Packaging
19.10.6.5.1. Prefilled
Needleless Syringes
19.10.6.5.2. Single
Dose and Multi-Dose Vial
19.10.6.6. Rest
of Middle East & Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$
Mn) and Forecasts, By Dosage Form
19.10.6.6.1. Intramuscular
Injection
19.10.6.6.2. Intradermal
Shot
19.10.6.6.3. Nasal
Spray
19.10.6.7. Rest
of Middle East & Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$
Mn) and Forecasts, By Age Group
19.10.6.7.1. 6
months to 4 Years
19.10.6.7.2. 4
Years to 18 Years
19.10.6.7.3. 18
Years to 49 Years
19.10.6.7.4. 49
Years to 65 Years
19.10.6.7.5. More
than 65 Years
19.10.6.8. Rest
of Middle East & Africa Flu Vaccine [Influenza Vaccine] Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
19.10.6.8.1. Doctors’
Offices
19.10.6.8.2. Healthcare
Clinics
19.10.6.8.3. Retail
Pharmacies
19.10.6.8.4. Hospitals
19.10.6.8.5. Others
19.11. Key
Segment for Channeling Investments
19.11.1. By
Country
19.11.2. By Vaccine
Type
19.11.3. By
Influenza Type
19.11.4. By
Type
19.11.5. By
Manufacturing Technology
19.11.6. By
Packaging
19.11.7. By
Dosage Form
19.11.8. By Age
Group
19.11.9. By
Distribution Channel
20. Latin
America Flu Vaccine [Influenza Vaccine] Market Analysis and Forecasts, 2021 -
2029
20.1. Overview
20.1.1. Latin
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn)
20.2. Latin
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Vaccine Type
20.2.1. Trivalent
Flu Vaccines
20.2.2. Quadrivalent
Flu Vaccines
20.3. Latin
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Influenza Type
20.3.1. Seasonal
20.3.2. Pandemic
20.3.3. Others
20.4. Latin
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Type
20.4.1. Live
Attenuated Influenza Vaccine (LAIV)
20.4.2. Inactivated
Influenza Vaccine (IIV)
20.4.3. Recombinant
Influenza Vaccine (RIV)
20.5. Latin
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Manufacturing Technology
20.5.1. Egg
Based
20.5.2. Cell
Based
20.6. Latin
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Packaging
20.6.1. Prefilled
Needleless Syringes
20.6.2. Single
Dose and Multi-Dose Vial
20.7. Latin
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Dosage Form
20.7.1. Intramuscular
Injection
20.7.2. Intradermal
Shot
20.7.3. Nasal
Spray
20.8. Latin
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Age Group
20.8.1. 6
months to 4 Years
20.8.2. 4 Years
to 18 Years
20.8.3. 18
Years to 49 Years
20.8.4. 49
Years to 65 Years
20.8.5. More
than 65 Years
20.9. Latin
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
20.9.1. Doctors’
Offices
20.9.2. Healthcare
Clinics
20.9.3. Retail
Pharmacies
20.9.4. Hospitals
20.9.5. Others
20.10. Latin
America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts,
By Country
20.10.1. Brazil
20.10.1.1. Brazil
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
20.10.1.1.1. Trivalent
Flu Vaccines
20.10.1.1.2. Quadrivalent
Flu Vaccines
20.10.1.2. Brazil
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
20.10.1.2.1. Seasonal
20.10.1.2.2. Pandemic
20.10.1.2.3. Others
20.10.1.3. Brazil
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
20.10.1.3.1. Live
Attenuated Influenza Vaccine (LAIV)
20.10.1.3.2. Inactivated
Influenza Vaccine (IIV)
20.10.1.3.3. Recombinant
Influenza Vaccine (RIV)
20.10.1.4. Brazil
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
20.10.1.4.1. Egg
Based
20.10.1.4.2. Cell
Based
20.10.1.5. Brazil
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
20.10.1.5.1. Prefilled
Needleless Syringes
20.10.1.5.2. Single
Dose and Multi-Dose Vial
20.10.1.6. Brazil
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
20.10.1.6.1. Intramuscular
Injection
20.10.1.6.2. Intradermal
Shot
20.10.1.6.3. Nasal
Spray
20.10.1.7. Brazil
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age Group
20.10.1.7.1. 6
months to 4 Years
20.10.1.7.2. 4
Years to 18 Years
20.10.1.7.3. 18
Years to 49 Years
20.10.1.7.4. 49
Years to 65 Years
20.10.1.7.5. More
than 65 Years
20.10.1.8. Brazil
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
20.10.1.8.1. Doctors’
Offices
20.10.1.8.2. Healthcare
Clinics
20.10.1.8.3. Retail
Pharmacies
20.10.1.8.4. Hospitals
20.10.1.8.5. Others
20.10.2. Argentina
20.10.2.1. Argentina
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Vaccine Type
20.10.2.1.1. Trivalent
Flu Vaccines
20.10.2.1.2. Quadrivalent
Flu Vaccines
20.10.2.2. Argentina
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Influenza Type
20.10.2.2.1. Seasonal
20.10.2.2.2. Pandemic
20.10.2.2.3. Others
20.10.2.3. Argentina
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Type
20.10.2.3.1. Live
Attenuated Influenza Vaccine (LAIV)
20.10.2.3.2. Inactivated
Influenza Vaccine (IIV)
20.10.2.3.3. Recombinant
Influenza Vaccine (RIV)
20.10.2.4. Argentina
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
20.10.2.4.1. Egg
Based
20.10.2.4.2. Cell
Based
20.10.2.5. Argentina
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Packaging
20.10.2.5.1. Prefilled
Needleless Syringes
20.10.2.5.2. Single
Dose and Multi-Dose Vial
20.10.2.6. Argentina
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Dosage Form
20.10.2.6.1. Intramuscular
Injection
20.10.2.6.2. Intradermal
Shot
20.10.2.6.3. Nasal
Spray
20.10.2.7. Argentina
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By Age
Group
20.10.2.7.1. 6
months to 4 Years
20.10.2.7.2. 4
Years to 18 Years
20.10.2.7.3. 18
Years to 49 Years
20.10.2.7.4. 49
Years to 65 Years
20.10.2.7.5. More
than 65 Years
20.10.2.8. Argentina
Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
20.10.2.8.1. Doctors’
Offices
20.10.2.8.2. Healthcare
Clinics
20.10.2.8.3. Retail
Pharmacies
20.10.2.8.4. Hospitals
20.10.2.8.5. Others
20.10.3. Rest
of Latin America
20.10.3.1. Rest
of Latin America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Vaccine Type
20.10.3.1.1. Trivalent
Flu Vaccines
20.10.3.1.2. Quadrivalent
Flu Vaccines
20.10.3.2. Rest
of Latin America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Influenza Type
20.10.3.2.1. Seasonal
20.10.3.2.2. Pandemic
20.10.3.2.3. Others
20.10.3.3. Rest
of Latin America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Type
20.10.3.3.1. Live
Attenuated Influenza Vaccine (LAIV)
20.10.3.3.2. Inactivated
Influenza Vaccine (IIV)
20.10.3.3.3. Recombinant
Influenza Vaccine (RIV)
20.10.3.4. Rest
of Latin America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Manufacturing Technology
20.10.3.4.1. Egg
Based
20.10.3.4.2. Cell
Based
20.10.3.5. Rest
of Latin America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Packaging
20.10.3.5.1. Prefilled
Needleless Syringes
20.10.3.5.2. Single
Dose and Multi-Dose Vial
20.10.3.6. Rest
of Latin America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Dosage Form
20.10.3.6.1. Intramuscular
Injection
20.10.3.6.2. Intradermal
Shot
20.10.3.6.3. Nasal
Spray
20.10.3.7. Rest
of Latin America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Age Group
20.10.3.7.1. 6
months to 4 Years
20.10.3.7.2. 4
Years to 18 Years
20.10.3.7.3. 18
Years to 49 Years
20.10.3.7.4. 49
Years to 65 Years
20.10.3.7.5. More
than 65 Years
20.10.3.8. Rest
of Latin America Flu Vaccine [Influenza Vaccine] Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
20.10.3.8.1. Doctors’
Offices
20.10.3.8.2. Healthcare
Clinics
20.10.3.8.3. Retail
Pharmacies
20.10.3.8.4. Hospitals
20.10.3.8.5. Others
20.11. Key
Segment for Channeling Investments
20.11.1. By
Country
20.11.2. By
Vaccine Type
20.11.3. By
Influenza Type
20.11.4. By
Type
20.11.5. By
Manufacturing Technology
20.11.6. By
Packaging
20.11.7. By
Dosage Form
20.11.8. By Age
Group
20.11.9. By
Distribution Channel
21. Competitive
Benchmarking
21.1. Market
Share Analysis, 2019
21.2. Global
Presence and Growth Strategies
21.2.1. Mergers
and Acquisitions
21.2.2. Product
Launches
21.2.3. Investments
Trends
21.2.4. R&D
Initiatives
22. Player Profiles
22.1. Abbott
22.1.1. Company
Details
22.1.2. Company
Overview
22.1.3. Product
Offerings
22.1.4. Key
Developments
22.1.5. Financial
Analysis
22.1.6. SWOT
Analysis
22.1.7. Business
Strategies
22.2. AstraZeneca
22.2.1. Company
Details
22.2.2. Company
Overview
22.2.3. Product
Offerings
22.2.4. Key
Developments
22.2.5. Financial
Analysis
22.2.6. SWOT
Analysis
22.2.7. Business
Strategies
22.3. CSL
Limited (Seqirus USA Inc.)
22.3.1. Company
Details
22.3.2. Company
Overview
22.3.3. Product
Offerings
22.3.4. Key
Developments
22.3.5. Financial
Analysis
22.3.6. SWOT
Analysis
22.3.7. Business
Strategies
22.4. Emergent
BioSolutions Inc.
22.4.1. Company
Details
22.4.2. Company
Overview
22.4.3. Product
Offerings
22.4.4. Key Developments
22.4.5. Financial
Analysis
22.4.6. SWOT
Analysis
22.4.7. Business
Strategies
22.5. F.
Hoffmann-La Roche Ltd
22.5.1. Company
Details
22.5.2. Company
Overview
22.5.3. Product
Offerings
22.5.4. Key
Developments
22.5.5. Financial
Analysis
22.5.6. SWOT
Analysis
22.5.7. Business
Strategies
22.6. GSK
22.6.1. Company
Details
22.6.2. Company
Overview
22.6.3. Product
Offerings
22.6.4. Key
Developments
22.6.5. Financial
Analysis
22.6.6. SWOT
Analysis
22.6.7. Business
Strategies
22.7. Novavax,
Inc.
22.7.1. Company
Details
22.7.2. Company
Overview
22.7.3. Product
Offerings
22.7.4. Key
Developments
22.7.5. Financial
Analysis
22.7.6. SWOT
Analysis
22.7.7. Business
Strategies
22.8. SANOFI
PASTEUR INC
22.8.1. Company
Details
22.8.2. Company
Overview
22.8.3. Product
Offerings
22.8.4. Key
Developments
22.8.5. Financial
Analysis
22.8.6. SWOT
Analysis
22.8.7. Business
Strategies
22.9. Serum
Institute of India Pvt. Ltd.
22.9.1. Company
Details
22.9.2. Company
Overview
22.9.3. Product
Offerings
22.9.4. Key
Developments
22.9.5. Financial
Analysis
22.9.6. SWOT
Analysis
22.9.7. Business
Strategies
22.10. Sinovac
Biotech Ltd.
22.10.1. Company
Details
22.10.2. Company
Overview
22.10.3. Product
Offerings
22.10.4. Key
Developments
22.10.5. Financial
Analysis
22.10.6. SWOT
Analysis
22.10.7. Business
Strategies
22.11. Other
Market Participant
23. Key
Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.